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Abstract 
Omeprazole (OME) exhibits low stability to light, heat and humidity. In stress conditions OME stability 
should improve under inclusion complex form with hydroxypropyl-β-cyclodextrin (HPβCD). Stability of 
OME, its physical mixture (PM) with HPβCD and OME:HPβCD inclusion complex was assessed during 
60 days. The inclusion complexes were prepared by kneading and freezedrying techniques and 
characterized by differential scanning calorimetry (DSC) and Fourier transform infrared spectroscopy 
(FTIR). A molecular modelling was also held to predict the most probable tridimensional conformation of 
inclusion complex OME:HPβCD. The inhibitory activity of free and complexed OME on selected 
enzymes, namely, papain (protease model of the proton pump) and acetylcholinesterase (enzyme present 
in cholinergic neurons and also involved in Alzheimer’s disease) was compared. The results obtained 
show that HPβCD do not protect against OME degradation, in any prepared powder, in the presence of 
light, heat and humidity. This may indicate that the reactive group of OME is not included in the HPβCD 
cavity. This fact is supported by molecular modelling data, which demonstrated that 2-pyridylmethyl 
group of OME is not included into the cyclodextrin cavity. In relation to enzymatic assays it was 
observed that free OME and OME in the binary systems showed identical inhibitory activity on papain 
and acethylcolinesterase, concluding that HPβCD do not affect OME activity on these two enzymes.
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Introduction 
Omeprazole (OME), which belongs to the family of
the gastric proton pump H+/K+-
solution, its stability is dependent on pH; in acidic and neutral conditions 
greater stability in alkaline medi
humidity [2-4]. 
Cyclodextrins (CDs) constitute a new class of pharmaceutical excipients
chemical and biological undesirable properties
non-covalent inclusion complexes with
from inclusion complexes include: increase of solubility of insoluble drugs; stabilization against 
oxidation, hydrolysis and photolysis reactions; 
[6]. Hydroxypropyl-β-cyclodextrin (HP
pharmaceutical formulation due to its high
complexing ability [7, 8]. Moreover, Loftsson 
with HPβCD, in aqueous solution, reporting 
knowing that the solubility of OME was increased, t
not, in the form of solid inclusion complexes, the 
– light, heat and humidity – so less degradation would 
conditions (light, heat, humidity). 
enzymes (papain and acetylcholinesterase
complexes prepared, was evaluated by determination of drug concentration that inhibited 50% of the 
enzyme activity (IC50). Papain is the enzyme normally chosen as an experimental model of enzyme 
kinetics of H+/K+-ATPase due to its easily accessible. Both enzymes
cysteine proteases and, therefore, its catalytic mechanism is identical
is an enzyme present in cholinergic neurons and in 
the control of nerve impulses. Its function is to catalyze the hydrolysis of the neurotransmitter 
acetylcholine to originate choline and 
the treatment of central nervous system degenerative diseases, particularly Alzheimer’s disease, which 
consists on the replacement of ace
therefore a great improvement of the patients’ life quality [13]. As the OME has the ability to cross the 
brain blood barrier [14] it was also intended to study the action of the drug on this enzyme in order to 
assess its efficiency as an AChE inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Structure of OME. 
 
Materials 
OME (Mr 345.4 g.mol-1) and HP
Roquette, respectively. Papain from papaya latex
acetylcholinesterase (AChE) type VI
Benzoyl-L-arginine-p-nitroanilide (L
nitrobenzoic] acid (DTNB); dimethyl sulfoxide (DMSO); methanol HPLC
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
Riedel-de Haën. 
 
 
 
 
 substituted benzimidazoles (Fig. 1), 
ATPase [1] but presents physical and chemical instability. 
it is rapidly degraded, showing 
um. In the solid state, the OME is degraded in presence of heat, light and 
 used to change
 of certain drugs. Due to its lipophilic cavity, CDs forms 
 poorly water-solube drugs [5]. The possible benefits obtained 
reduction or elimination of unpleasant effects and others
βCD) is a β-cyclodextrin derivative with a great interest for 
er solubility in aqueous solutions; very low 
et al. [9] published a study of the complexation of OME 
a solubility improvement of the drug (Kc 69 M
he aim of this study was to investigate 
OME would be more protected against
be protected agains degradation under stress 
The influence of HPβCD on the biological activity of OME on certain 
), the inhibitory activity of free OME and OME of 
 (papain and 
 [10]. Acetylcholinesterase (AChE) 
the neuromuscular junctions that plays a key role on 
acetate [11, 12]. The use of AChE inhibitors is a recent approach on 
tylcholine by decreasing the degradation of the neurotransmitter, and is 
 
βCD (Mr 1387.15 g.mol-1) were kindly donated by MEDINFAR 
, 22.7 U/mg solid, 25.
-S, extracted from electric eel 349 U/mg solid, 411 U/mg protein
-BAPA); acetylthiocholine iodide (AChI); 5,5’
-Grade (MeOH)
 were all from Sigma. Sodium acetate from 
is an inhibitor of 
In aqueous 
 the physico-
 
toxicity and good 
-1). Thus, 
whether or 
 stress conditions 
the inclusion 
H+/K+-ATPase) are 
and by 
8 U/mg protein; 
; 
-dithiobis [2-
; 4-(2-
Methods 
 
Physical mixtures (PM) 
 
The physical mixtures were prepared by mixing OME and HPβCD in 1:1 M molar (Fisher-Kendall 
Scientific Co., 12-811, USA) for 10 minutes.  
 
Kneading (KN) 
 
HPβCD (1.6210 g) was wetted by a basic aqueous solution (pH 10.3) (≈ 50% w/w) in a ceramic mortar 
and then the required amount of OME (0.4040 g) was slowly added (1:1 M ratio) and kneaded for 30 min 
until a slurry was obtained. 
 
Freeze-drying (FD) 
 
HPβCD (0.8103 g) was dissolved in a basic aqueous solution (pH 10.3) and then the required amount of 
OME (0.2017 g) was added (1:1 M ratio) under stirring for 24 h. Furthermore, the resultant solution was 
frozen in liquid nitrogen and was lyophilized (Christ Alpha 1–4 freezedryer, B. Braun Biotech 
International, Germany). 
 
Differential scanning calorimetry (DSC) 
 
The thermal behaviour of the different powders were performed by DSC (TC 11, TA Processor, Mettler, 
Germany) using 4 mg samples in closed aluminum pans at a heating rate of 10 ⁰C/min in 30 ⁰C – 300 ⁰C.  
 
Infrared spectroscopy (IR) 
 
Fourier transform-infrared spectroscopy (FT-IR) Infrared spectra were performed on a spectrophotometer 
(Nicolet spectrophotometer, model Impact 400, USA) using the KBr disk method and scanned from 4000 
to 400 cm-1. 
 
Molecular simulation 
 
The MOE program was used to construct the OME and HPβCD molecules. The HPβCD molecule was 
obtained from βCD structure, by adding the substitution hydroxypropyl groups. allowed (hydroxypropyl 
groups). The geometries of the HPβCD and OME molecules were optimized with a semi-empirical 
quantum method AM1 [15] using the program Gaussian03 (www.gaussian.com). Subsequently held the 
inclusion of the molecule of OME (previously optimized) in the cavity of HPβCD, previously 
constructed, and was performed a calculation of molecular docking in order to study the conformational 
space of the CD and get the most favourable conformation of the complex. 
 
Stability  Studies  
 
Stability studies of free OME and PM, KN and FD powder samples were carried out in glass bottles 
sealed with rubber stopper and parafilm, in three different environmental conditions, 24 h per day (during 
60 days):  
a) actinic light at to room temperature and humidity; 
b) 40 °C and 75% relative humidity (Vötsch, Industrietechnick, VC 2033); 
c) 4 ºC in dark. 
 
To assess the degradation of free OME (pure) and complexed OME (PM, KN and FD) aliquots were 
analyzed at 28th and 60th days by HPLC at a concentration of 20 µg/mL (dissolved in MeOH). As 
reference, samples were analyzed by HPLC before the start of this test (time 0 days). 
 
HPLC 
 
The apparatus of HPLC (FinniganTM Surveyor® Plus Modular LC System) was equipped with a column 
Purospher ® STAR RP-18 (Merck) with a UV detector set at 305 nm and the Xcalibur software. The 
following analytical conditions were used: injection volume of 25 µL, flow 1.0 mL/min and mobile 
phase: methanol/ammonia-water (60/40, v/v) pH 8.4. The running time was 20 min. 
HPLC  
 
Enzymatic  Studies  
 
Kinetic experiments were performed for the enzyme papain and AChE, which were followed by UV-Vis 
spectroscopy in the presence and absence of OME and binary mixtures (PM, KN and FD). The control 
assay for each enzymatic reaction, corresponded, then, the absence of OME or binary mixture in the 
reaction medium and was considered 100% activity. 
 
eq. 1 
 
where enzim. rate sample is the enzymatic rate, in absorbance per minute, of the reaction containing OME 
or binary mixture and enzim. rate control is the enzymatic rate, in absorbance per minute, of the control 
reaction (absence of OME). 
 
Papain 
 
The enzymatic activity of papain was quantified by adapting the method described by Zhao et al. [16]. 
Papain solution (0.2 mg/mL) in sodium acetate buffer 50 mM pH 4.8 (2.5 mM EDTA e 7.5 mM DTT) 
was prepared in order to create an acidic environment similar to the parietal cells in the stomach, at the 
proton pump. The papain solution prepared was activated by DTT for 2 h at room temperature. The L-
BAPA (30 mM in DMSO) was the substrate for papain and was followed by the formation of product 4-
nitroaniline at 410 nm. The absorbance at 410 nm was read at intervals of 1 min for 10 min. The graph of 
absorbance (Abs) versus time (min) was plotted and the the rate of reaction was obtained from the 
equation: 
bmxy +=   eq. 2        
where y corresponds to the absorbance, m to the rate of reaction and x to the time. 
The OME concentrations were varied from 0.109 to 0.579 mM in order to determine the concentration 
that inhibits 50% of enzyme activity (IC50). We used the concentration of OME who originated the IC50 in 
the sample free of OME for tests with binary mixtures and with free HPβCD. The assays were performed 
in triplicate. 
 
Acetylcholinesterase (AChE) 
 
The enzymatic activity of AChE was measured by adapting the method described by Falé et al. [17]. The 
substrate was acetylthiocholine iodide (AChI, 1 mM in distilled water).The product formed reacts with 
DTNB (3 mM in HEPES buffer 50 mM pH 8 with 50 mM NaCl and 20 mM MgCl2.6H2O), producing a 
colored compound, followed by reaction at 405 nm. The absorbance at 405 nm was read at intervals of 1 
min for 5 min. The rate of the reaction was obtained by the same method that was used in papain. 
The concentrations of free OME and OME in binary systems were varied from 0.015 mM to 0.434 mM in 
order to determine the concentration that inhibits 50% of enzyme activity (IC50). Kinetic assays of AChE 
with free HPβCD with two different concentrations 0.506 and 0.203 mM were also performed. 
The assays were performed in triplicate. 
 
Statistical analysis 
 
The significance of the IC50 values obtained on the inhibitory activity tests of OME and binary mixtures 
on AChE was tested by ANOVA (Analysis of Variance) F-Snedecor distribution with a range of 95%. 
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Results and Discussion 
 
Differential scanning calorimetry (DSC) 
 
The DSC thermogram of OME shows one characteristic sharp endothermic peak at around 156 ⁰C, 
indicating the melting point of the drug, followed by an exothermic effect at 173 °C, relative to its 
thermal decomposition (Fig. 2a). The thermogram corresponding to HPβCD (Fig. 2b) shows a broad 
endothermic effect between 60 and 120 °C, attributed to the loss of water molecules in the cavity of the 
CD [18]. For the PM, both the characteristic peaks of the drug (melting peak) as the effect of HPβCD 
endothermic (dehydration) are present (Fig. 2c), without deviation of the OME melting point, 
demonstrating absence of inclusion complexes. The thermogram of the sample KN (Fig. 2d) shows an 
endothermic peak, corresponding to the OME melting point, but with low intensity and relatively broader 
than the pure drug, also suffering from a shift to a lower temperature. This indicates that some interaction 
between OME and HPβCD occurred. The disappearance of the OME melting point peak in FD sample 
suggests an incorporation of the drug in the HPβCD cavity (Fig. 2e). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 DSC thermograms of (a) OME, (b) HPβCD, (c) PM, (d) KN and (e) FD. 
 
 
Infrared spectroscopy (IR) 
 
The FTIR spectrum of OME (Fig. 3a) shows two characteristic bands at 1625.99 cm -1, corresponding to 
stretching link vibration (C=C–N and S–C=N), and at 1203.31 cm-1  relative to the Ar-C-OCH3 vibration 
accompanied by resonance band at 1075 cm-1 (Fig. 3b) [4]. These two bands were used to analyze the 
interaction between OME and HPβCD. 
None of the binary mixtures presented the formation of new bands, indicating that no covalent bond was 
established in the complexes formed [19]. 
The characteristic bands of OME and HPβCD are present on the IR spectrum of PM, indicating that there 
was no interaction between the CD cavity and the groups responsible for the relevant IR absorption (Fig. 
3c).  
Identical result was observed for the KN sample (Fig. 3d), although the band at 1203.31 cm-1 have less 
intensity than on the PM, reinforcing thus the idea of having partial interaction between the OME and 
CDs molecules, as mentioned above for the results obtained by DSC. 
In FD sample it can be observed that the OME absorption band at 1625.99 cm-1 has disappeared, 
appearing a band at 1647.81 cm-1 (Fig. 3e), which is characteristic of HPβCD and corresponds to the 
elongation of the H-O-H bonds [20]. The intensity of the band at 1203.31 cm-1 is also significantly 
decreased. These results suggest that restrictions on the vibration of C=C–N, S–C=N and Ar–C–OCH3 
bonds due to its inclusion within the cavity of the CD probably occured. 
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  c) 
d) 
e) 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 IR spectra of (a) OME, (b) HP
 
 
Molecular simulation 
 
The most probable tridimensional conformation 
by molecular simulation (Fig. 4).
In the simulation model it is possible 
HPβCD cavity while the 2-pyridylmethyl 
complexation of -68,22 kJ/mol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 Molecular docking of OME with HP
 
 
Stability  Studies  
 
Stability of both pure and complexed OME was evaluated under distinct environmental conditions such 
as light, heat and humidity. 
 2000  
βCD, (c) PM, (d) KN and (e) FD. 
of inclusion complex OME:HPβCD 
 
to observe that the benzimidazole ring of OME is included into the 
group is outside the HPβCD cavity, featuring an energy of 
βCD molecule. 
   a) 
    b) 
      c) 
  d) 
e) 
 1000  
Wave number (cm-
1
) 
could be observed 
At time 0 days, all samples (free OME, PM, KN an
chromatograms it was found that different samples had no degradation products with the appearance of a 
well-defined peak, relative to OME
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5 HPLC chromatograms of OME in the different samples (PM, KN, FD) at 0 days.
 
Table 1 presents the results obtained for the degradation of OME in the various samples (free OME, PM, 
KN and FD) when exposed to different environmental 
physical aspect. 
On Table 1 it can be seen that actinic light 
of OME. It is also possible to conclude that OME under inclusion complex is 
OME in presence of actinic light and 40 ºC with 75% RH.
HPβCD did not increase drug stability to light, heat and humidity, instead led to an increase in its rate of 
decomposition. This can be attributed to the 
different modes of inclusion for the same molecule; 
accelerated, retarded or remain the same 
remain outside the cavity of the HP
accelerate the degradation of the drug through a reaction between 2
groups. There was also a change in the colo
binary systems (Fig. 6), which suggests a relationship between the degradation degree and the colo
the samples. 
Thus, it seems not to be advantageous to p
protection despite this CD significantly increase the solubility of the drug
 
 
Table 1 - Degradation (%) of free OME and OME present on 
complexes obtained by kneadind - KN and 
60 days. 
 
 
 
 % OME degradado 
 Actinic light  
Time (days) Pure OME 
OME:HPβCD
PM
 
KN
 
0 0 0 0 
28 8.66 37.97 75.47
60 26.20 59.66 70.13
d FD) were analyzed by HPLC. By the 
 in each sample, with retention time between 7.7 and 7.8 min (Fig.
conditions for 60 days and the Fig.
is the environmental condition which cause
more degr
 Unlike desired, complexation of OME with 
CD used (HPβCD). Different types of CD may lead to 
depending on CD, the degradation of the drug can be 
[21]. The fact of  2-pyridylmethyl group from OME might 
βCD, as shown by supporting data from molecular simulation, may 
-pyridymethyl group and 
ur of the different samples over the 60 days, m
repare inclusion complexes OME:HPβCD
 [9]. 
different binary mixtures (
the freeze-drying – FD methods) at different environmental conditions over 
40 ºC, 75% humidity  
 Pure 
OME 
OME:HPβCD Pure 
OME FD
 
PM
 
KN
 
FD
 
0 0 0 0 0 0 
 76.06 10.26 10.69 13.93 100.00 0 
 99.27 15.26 11.94 17.43 100.00 0 
analysis of 
 5). 
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s more degradation 
adable than pure 
CD hydroxyl 
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0 0 1.28 
  
 
 
 
 
 
 
 
 
 
Fig. 6 Physical aspect of pure OME and FD sample.
 
Enzymatic  Studies  
Biological activity of pure OME and OME as inclusion complex
papain and AChE. 
Papain 
The IC50 value obtained for the pure OME was 0
of the papain was obtained for the samples PM, KN and FD (Fig.
activity of OME is not affected even in the presence of HP
group of the drug, responsible for binding to the enzyme and, consequently,
outside the CD cavity, enabling the reactio
IC50. An enzymatic assay of papain with free HP
that the enzyme activity is equal to the control assay.
with the activity of papain, and therefore, as expected, it 
various binary mixtures. Similar results were reported by Gubica 
TMβCD ((2,3,6-tri-O-methyl)-β-
lyase with the substrate L-tryptophan
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 Papain activity (%) in presence of pure and complexed OME. All samples had an OME 
concentration of 0.425 mM (n = 3).
 
In
cl
u
sio
n
 
co
m
pl
ex
es
 
(fr
ee
ze
-
dr
yi
n
g) 
 
Pu
re
 
O
M
E 
0 days 
 
 was assessed by enzymatic assays using 
.425 mM. At this OME concentration the same inhibition 
 7), concluding that the inhibitory 
βCD. This could mean that the functional 
 its inhibition
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is obtained similar enzyme activities between the 
et al. [22], where the presence of 
cyclodextrin) did not affect the enzymatic reaction of tryptophan 
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, shall remain 
indole-
 
Acetylcholinesterase 
The inhibitory activity of OME on acetylcholinesterase had not yet been determined in any published 
study. OME concentrations were varied from 0.015 to 0.434 mM in order to determine the concentration 
that inhibits 50% of enzyme activity (IC50). The IC50 value obtained for the pure OME was 0.224 ± 
0.016 mM. This IC50 value differs from the IC50 of galantamine (1.07 ± 0.18 lM) [23], an AChE 
inhibitor drug used to treat Alzheimer’s disease [24]. However, the OME has a higher capacity of inhibit 
AChE compared to some natural compounds, particularly the monoterpenes, the major components of 
essential oils extracted from plants, flowers and fruits. 1.8-cineole and α-pinene are the most active 
monoterpenes with IC50 values of 0.670 mM and 0.630 mM, respectively. The difference in the inhibitory 
effect of the various compounds in relation to AChE is related to the enzyme binding site, which may 
occur directly in the active site or in peripheral binding site or both sites [25]. The OME is therefore a 
substance with a promising structure that could be tested as a lead molecule for the development of new 
compounds that are more effective in the inhibition of AChE. To infer whether HPβCD affects the 
inhibitory effect of OME on AChE activity, IC50 values of OME in the different binary systems (PM, KN 
and FD) were determined. The IC50 values were 0.255 ± 0.011 mM for PM, 0.216 ± 0.048 mM for KN 
and 0.279 ± 0.004 mM for FD (Fig. 8). The IC50 values are similar for the OME in the different binary 
systems and free OME (pure) as was proved through statistical analysis (ANOVA, F-test for a probability 
of P = 0.05), that these values are not significantly different (F (3.78) <Fcrit (4.07)). This indicates that 
even when the OME is complexed with HPβCD, the functional group of the drug responsible for binding 
to the enzyme and, consequently, inhibition of the same, shall remain outside the cavity of the CD, 
allowing the reaction with AChE, giving therefore rise to the identical value of IC50 between free and 
complexed OME, as was the case with papain. An enzymatic assay of AChE with free HPβCD (without 
OME) was also carried out observing that the enzyme activity is equal to the control assay. Thus, it seems 
that, as in the assay with papain, the CD used does not affect the activity of AChE. 
 
 
 
 
 
 
 
 
 
Fig 8. Acetylcholinesterase IC50 values (mM) for the different samples (free OME, PM, KN and FD). 
 
Conclusion 
The methods used to characterize the prepared inclusion complexes showed that there was interaction of 
the OME with the HPβCD cavity. However HPβCD didn´t protect against OME degradation in the 
presence of light, heat and humidity, indicating that the reactive group of OME was not probably included 
into the CD cavity, as evidence by the data from molecular simulation. Enzymatic assays showed that free 
OME and OME in binary systems presented identical inhibitory activity on papain and 
acethycolinesterase, concluding that HPβCD didn´t affect OME activity on both enzymes. Moreover free 
HPβCD didn´t affect neither papain nor acetylcholinesterase activity. 
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